A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a ...
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review FGFRi are effective treatment strategies for patients with advanced ...
The median duration of response on erdafitinib among patients with FGFR fusions or mutations in the NCI-MATCH was <6 months. This may in part be due to low dependency on FGFR signaling in the genetic ...
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types ...
A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations. Video Player is loading.
The novel intravesical drug delivery system releases erdafitinib locally within the bladder while limiting systemic toxicities. Findings from the first-in-human study of TAR-210 were presented at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback